CA2460704A1 - Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes - Google Patents

Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes Download PDF

Info

Publication number
CA2460704A1
CA2460704A1 CA002460704A CA2460704A CA2460704A1 CA 2460704 A1 CA2460704 A1 CA 2460704A1 CA 002460704 A CA002460704 A CA 002460704A CA 2460704 A CA2460704 A CA 2460704A CA 2460704 A1 CA2460704 A1 CA 2460704A1
Authority
CA
Canada
Prior art keywords
lysine
serine
sequence seq
acetylated
phosphorylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002460704A
Other languages
English (en)
French (fr)
Inventor
Sylviane Muller
Fanny Sylvie Michele Monneaux
Jean-Paul Briand
Gilles Guichard
Jean-Gerard Guillet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2460704A1 publication Critical patent/CA2460704A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CA002460704A 2001-09-18 2002-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes Abandoned CA2460704A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR01/12041 2001-09-18
FR0112041A FR2829768B1 (fr) 2001-09-18 2001-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
PCT/FR2002/003186 WO2003025014A2 (fr) 2001-09-18 2002-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes

Publications (1)

Publication Number Publication Date
CA2460704A1 true CA2460704A1 (fr) 2003-03-27

Family

ID=8867384

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002460704A Abandoned CA2460704A1 (fr) 2001-09-18 2002-09-18 Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes

Country Status (7)

Country Link
US (3) US7872098B1 (cg-RX-API-DMAC10.html)
EP (2) EP2338908A1 (cg-RX-API-DMAC10.html)
JP (1) JP4160505B2 (cg-RX-API-DMAC10.html)
AU (1) AU2002362383B2 (cg-RX-API-DMAC10.html)
CA (1) CA2460704A1 (cg-RX-API-DMAC10.html)
FR (1) FR2829768B1 (cg-RX-API-DMAC10.html)
WO (1) WO2003025014A2 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2459811C (en) * 2001-09-06 2012-03-13 Cnrs-Centre National De La Recherche Scientifique Modified peptides and their use for the treatment of autoimmune diseases
FR2931360B1 (fr) * 2008-05-20 2012-05-18 Centre Nat Rech Scient Nanoparticules contenant un peptide, vecteurs les contenant et utilisations pharmaceutiques desdits nanoparticules et vecteurs
ES2618402T3 (es) * 2011-12-13 2017-06-21 Centre National De La Recherche Scientifique Péptidos modificados y su uso para tratar enfermedades autoinmunitarias
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases
WO2021198135A1 (en) * 2020-03-29 2021-10-07 Immupharma France Sa Method of treating viral infections
CN119241701B (zh) * 2024-09-27 2026-04-28 珠海丽禾医疗诊断产品有限公司 U1-70k结合蛋白、制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2459811C (en) * 2001-09-06 2012-03-13 Cnrs-Centre National De La Recherche Scientifique Modified peptides and their use for the treatment of autoimmune diseases

Also Published As

Publication number Publication date
WO2003025014A3 (fr) 2004-02-19
JP2005510469A (ja) 2005-04-21
EP2338908A1 (fr) 2011-06-29
US20140004136A1 (en) 2014-01-02
FR2829768B1 (fr) 2003-12-12
US7872098B1 (en) 2011-01-18
EP1427755A2 (fr) 2004-06-16
WO2003025014A2 (fr) 2003-03-27
JP4160505B2 (ja) 2008-10-01
AU2002362383B2 (en) 2008-10-09
US8475800B2 (en) 2013-07-02
FR2829768A1 (fr) 2003-03-21
US20120149652A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
US7560100B2 (en) Mixtures of polypeptides, compositions containing and processes for preparing same, for treating neurodegenerative diseases
US20080118553A1 (en) Tannate salt form of polypeptide mixtures, their preparation and use
US20070059798A1 (en) Polypeptides useful for molecular weight determinations
JPH10509172A (ja) ヒトミエリン塩基性タンパク質のペプチドアナログを用いた多発性硬化症の処置のための方法
JP6364352B2 (ja) 部分的ｍｈｃコンストラクト及びその使用方法
KR0159046B1 (ko) 포유류의 자기면역 포도막망막염의 치료 또는 예방방법
US20140004136A1 (en) Phosphorylated derivatives of a u1-70k peptide and their use in the treatment of autoimmune pathologies
EP1750741B1 (en) Methods of treating disease with random copolymers
US5753625A (en) Treatment for inhibiting the progression of autoimmune disease
CA2459811C (en) Modified peptides and their use for the treatment of autoimmune diseases
AU2001247965A1 (en) Therapeutic and diagnostic methods for ulcerative colitis and associated disorders
FR2909879A1 (fr) Utilisation d'un heptapeptide a activite anxiolytique pour la preparation de medicaments et de complements alimentaires
AU2014291149B2 (en) Therapeutic agent for disease based on inhibitory effect of macrophage migration inhibitory factor
JP4642469B2 (ja) カルシニューリンの恒常的活性化阻害剤
EP0095426A1 (fr) Polypeptides de synthèse contenant au moins une séquence de la sous-unité B1 de la toxine cholérique et médicaments les contenant
EA019358B1 (ru) Аллель- и изотип-специфическая интервенция в ассоциированные с аутоиммунными заболеваниями молекулы класса ii мнс при помощи пептидов
EP2279744A2 (en) ApoE mimetic agents

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20130320